Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics
Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue Estimates
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
HALO-Flight Strengthens its Texas-based Air Med Fleet with Additional Bell 407GXi Purchase Order
Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT?
11,095 Halozyme Therapeutics, Inc. $HALO Shares Purchased by Gibbs Wealth Management